A database of FDA approved therapeutic peptides and proteins
ID1005 | ThPPIDTh1002 | NameCetuximab | Peptide SequenceHeavy chain:QVQLKQSG Full view | Length243 | Functional ClassificationIIIc | DiseaseCancer | BrandErbitux | CompanyImClone Systems Inc | Physical AppearanceSterile, clear, colorless liquid of pH 7.0-7.4, which may contain a small amount of easily visible, white, amorphous cetuximab particulates | Route of AdministartionIntravenous infusion | CategoryAntineoplastic Agents | TargetEpidermal growth factor receptor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
ID1025 | ThPPIDTh1004 | NameDenileukin diftitox | Peptide SequenceMGADDVVDSSKSFVMENFSS Full view | Length255 | Functional ClassificationIIb | DiseaseCancer | BrandOntak | CompanySeragen Inc | Physical AppearanceSterile, white, preservative-free, lyophilized powder. | Route of AdministartionIntravenous(IV) administration | CategoryAntineoplastic Agents | TargetInterleukin-2 receptor subunit alpha,Interleukin-2 receptor subunit beta,Cytokine receptor common subunit gamma |
ID1028 | ThPPIDTh1005 | NameEtanercept | Peptide SequenceLPAQVAFTPYAPEPGSTCRL Full view | Length255 | Functional ClassificationIIa | DiseaseImmunological | BrandEnbrel | CompanyImmunex Corp | Physical AppearanceLyophilized powder. | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetTumor necrosis factor,Tumor necrosis factor receptor superfamily member 1B,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c,Lymphotoxin-alpha,Low affinity immunoglobulin gamma Fc region re |
ID1029 | ThPPIDTh1005 | NameEtanercept | Peptide SequenceLPAQVAFTPYAPEPGSTCRL Full view | Length255 | Functional ClassificationIIa | DiseaseImmunological | BrandEnbrel Sureclick | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetTumor necrosis factor,Tumor necrosis factor receptor superfamily member 1B,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c,Lymphotoxin-alpha,Low affinity immunoglobulin gamma Fc region re |
ID1038 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandEligard | CompanyAtrix Labs/QLT In | Physical AppearanceSuspension | Route of AdministartionSubcutaneous Injection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1039 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandEnantone | CompanyTakeda | Physical AppearanceSolution | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1040 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLeuplin | CompanyTakeda | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1041 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLeuProMaxx | CompanyBaxter/Teva | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1042 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLeupromer | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1043 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLupron | CompanyAbbott/TAP Pharmaceuticals | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1044 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandLutrate | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1045 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandMemryte | CompanyCuraxis | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1046 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandProstap 3 | CompanyTakeda UK Limited | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1047 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandProstap SR | CompanyTakeda UK Limited | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1048 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandViadur | CompanyBayer AG | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1049 | ThPPIDTh1008 | NamePeginterferon alfa-2a | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandPegasys | CompanyHoffman-La Roche Inc | Physical AppearanceSterile, preservative-free, colorless to light yellow injectable solution | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1055 | ThPPIDTh1009 | NameAlteplase | Peptide SequenceSYQVICRDEKTQMIYQQHQS Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandActivase | CompanyGenentech Inc | Physical AppearanceSterile, white to off-white, lyophilized powder | Route of AdministartionIntravenous | CategoryThrombolytic Agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1059 | ThPPIDTh1010 | NameInterferon alfa-n1 | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseInfectious /Immunological | BrandWellferon | CompanyGlaxoSmithKline | Physical AppearanceSolution | Route of AdministartionInjection | CategoryAntiviral Agents, Immunologic factors, Immunosuppressiv agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1064 | ThPPIDTh1011 | NameDarbepoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandAranesp | CompanyAmgen Inc | Physical AppearanceSterile, colorless, preservative-free solution containing polysorbate | Route of AdministartionIntravenousor Subcutaneous administration | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1067 | ThPPIDTh1012 | NameReteplase | Peptide SequenceSYQGNSDCYFGNGSAYRGTH Full view | Length255 | Functional ClassificationIb | DiseaseHematological,Metabolic | BrandRetavase | CompanyCentocor | Physical AppearanceSterile, white, lyophilized powder | Route of AdministartionIntravenous Injection | CategoryFibrinolytic Agents, Thrombolytic agents | TargetPlasminogen,Fibrinogen alpha chain,Urokinase plasminogen activator surface receptor,Plasminogen activator inhibitor 1 |
ID1071 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandBinocrit | CompanySandoz | Physical AppearanceClear colourless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1072 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEpocept | CompanyLupin pharma | Physical AppearanceN.A. | Route of AdministartionInjection | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1073 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEpofit | CompanyIntas pharma | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1074 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEpogen | CompanyAmgen Inc. | Physical AppearanceSterile, colorless liquid | Route of AdministartionSubcutaneous Injection | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1075 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEpogin | CompanyChugai | Physical AppearanceN.A. | Route of AdministartionSubcutaneous or by Intravenous. | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1076 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEprex | CompanyJanssen-Cilag. Ortho Biologics LLC | Physical AppearanceSolution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1077 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandNanokine | CompanyNanogen Pharmaceutical biotechnology, Vietnam) | Physical AppearanceSterile, white, lyophilized powder. The reconstituted preparation with 1 ml solvent (containing 0.9% benzyl alcohol) results in a clear, colorless solution. | Route of AdministartionInjection | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1078 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandProcrit | CompanyOrtho Biotech | Physical AppearanceSterile, colorless liquid in an isotonic sodium chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate buffered solution | Route of AdministartionIntravenous(IV) or Subcutaneous (SC) administration. | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1098 | ThPPIDTh1014 | NameSalmon Calcitonin | Peptide SequenceCSNLSTCVLGKLSQELHKLQ Full view | Length32 | Functional ClassificationIb | DiseaseOsteological | BrandCalcimar | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous or Intramuscular Injection | CategoryBone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | TargetCalcitonin receptor |
ID1099 | ThPPIDTh1014 | NameSalmon Calcitonin | Peptide SequenceCSNLSTCVLGKLSQELHKLQ Full view | Length32 | Functional ClassificationIb | DiseaseOsteological | BrandFortical | CompanyN.A. | Physical AppearanceNasal spray | Route of AdministartionIntranasal use | CategoryBone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | TargetCalcitonin receptor |
ID1100 | ThPPIDTh1014 | NameSalmon Calcitonin | Peptide SequenceCSNLSTCVLGKLSQELHKLQ Full view | Length32 | Functional ClassificationIb | DiseaseOsteological | BrandMiacalcin | CompanyNovartis | Physical AppearanceSolution | Route of AdministartionSubcutaneous or Intramuscular Injection | CategoryBone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | TargetCalcitonin receptor |
ID1110 | ThPPIDTh1015 | NameInterferon alfa-n3 | Peptide SequenceAlpha-2A:CDLPQTHSLG< Full view | Length235 | Functional ClassificationIb | DiseaseImmunological | BrandAlferon | CompanyInterferon Sciences Inc. | Physical AppearanceSolution | Route of AdministartionInjection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1111 | ThPPIDTh1015 | NameInterferon alfa-n3 | Peptide SequenceAlpha-2A:CDLPQTHSLG< Full view | Length235 | Functional ClassificationIb | DiseaseImmunological | BrandAlferon LDO | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1112 | ThPPIDTh1015 | NameInterferon alfa-n3 | Peptide SequenceAlpha-2A:CDLPQTHSLG< Full view | Length235 | Functional ClassificationIb | DiseaseImmunological | BrandAlferon N Injection | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1117 | ThPPIDTh1016 | NamePegfilgrastim | Peptide SequenceMTPLGPASSLPQSFLLKCLE Full view | Length175 | Functional ClassificationIb | DiseaseImmunological | BrandNeulasta | CompanyAmgen Inc. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents, Anti-neutropenic agents | TargetGranulocyte colony-stimulating factor receptor,Neutrophil elastase |
ID1120 | ThPPIDTh1017 | NameSargramostim | Peptide SequenceAPARSPSPSTQPWEHVNAIQ Full view | Length127 | Functional ClassificationIb | DiseaseImmunological | BrandLeucomax | CompanyNovartis | Physical AppearanceSolution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryImmunosuppressive Agents | TargetGranulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
ID1121 | ThPPIDTh1017 | NameSargramostim | Peptide SequenceAPARSPSPSTQPWEHVNAIQ Full view | Length127 | Functional ClassificationIb | DiseaseImmunological | BrandLeukine | CompanyBerlex Laboratories Inc | Physical AppearanceSterile, preserved (1.1% benzyl alcohol), injectable solution (500 mcg/mL) and also as sterile, white, preservative free lyophilized powder (250 mcg) that requires reconstitution with 1 mL sterile water for Injection | Route of AdministartionSubcutaneous Injection (SC) or Intravenous infusion (IV) | CategoryImmunosuppressive Agents | TargetGranulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
ID1129 | ThPPIDTh1018 | NameSecretin | Peptide SequenceHSDGTFTSELSRLRDSARLQ Full view | Length27 | Functional ClassificationIV | DiseaseHormonal disorders | BrandSecreFlo | CompanyRepligen Corp | Physical AppearanceLyophilized white powder | Route of AdministartionIntravenous infusion | CategoryDiagnostic Agents | TargetSecretin receptor |
ID1130 | ThPPIDTh1018 | NameSecretin | Peptide SequenceHSDGTFTSELSRLRDSARLQ Full view | Length27 | Functional ClassificationIV | DiseaseHormonal disorders | BrandSecremax | CompanyRepligen Corp | Physical AppearanceSolution | Route of AdministartionIntravenous | CategoryDiagnostic Agents | TargetSecretin receptor |
ID1135 | ThPPIDTh1019 | NamePeginterferon alfa-2b | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandPEG-Intron | CompanySchering Corp | Physical AppearancePowder | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1136 | ThPPIDTh1019 | NamePeginterferon alfa-2b | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandUnitron PEG | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1145 | ThPPIDTh1021 | NameThyrotropin Alfa | Peptide SequenceAlpha chain:APDVQDC< Full view | Length204 | Functional ClassificationIV | DiseaseCancer | BrandThyrogen | CompanyGenzyme Inc | Physical AppearanceLyophilized powder | Route of AdministartionIntramuscular preferably the buttocks | CategoryDiagnostic Agents | TargetThyrotropin receptor |
ID1148 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAdvate | CompanyN.A. | Physical AppearancePowder form | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1149 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandAlphanate | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1150 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandBioclate | CompanyBaxter Healthcare Corporation, Hyland Division and Genetics Institute, Inc. | Physical AppearanceSterile, nonpyrogenic, off-white to faint yellow, lyophilized powder | Route of AdministartionIntravenous infusion | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1151 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandHelixate FS | CompanyN.A. | Physical AppearanceSterile, stable, purified, nonpyrogenic, dried concentrate | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1152 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandHemofil M | CompanyN.A. | Physical AppearanceDry concentrate | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1153 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandHyate:C | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1154 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandKoate-HP | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |
ID1155 | ThPPIDTh1022 | NameAntihemophilic Factor | Peptide SequenceATRRYYLGAVELSWDYMQSD Full view | Length255 | Functional ClassificationIa | DiseaseHematological,Metabolic | BrandKogenate FS | CompanyN.A. | Physical AppearancePowder | Route of AdministartionIntravenous Injection | CategoryCoagulants and Thrombotic agents | TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2 |